DBV Technologies S.A.DBVTNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Financials Growth Insiders

Latest News

globenewswire.com

DBV Technologies to Participate in Upcoming March Investor Conferences

Châtillon, France, March 4, 2026 DBV Technologies to Participate in Upcoming March Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in March: Citizens Life Sciences Conference – March 10, 2026 Format: Fireside Chat Time: 1:40pm ET Leerink Partners Global Healthcare Conference – March 11, 2026 Format: 1 on 1 Meetings Sign up to watch the live webcast of the Citizens JMP presentation here. A replay will also be available on the Events section of the Company's website 90 days after the event.

globenewswire.com

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo group Approximately 60% of children treated with the VIASKIN® Peanut Patch increased their eliciting dose by at least two doses at month 12, compared to 23% in the placebo group 24% of children on placebo decreased their eliciting dose between the baseline and month 12 double-blind, placebo-controlled food challenge, compared to only 6.4% of children treated with the VIASKIN® Peanut Patch DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the company shared additional positive data from the successful Phase 3 VITESSE clinical trial as an oral presentation today at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2026 Annual Meeting, in Philadelphia, PA. VITESSE, the largest food allergy immunotherapy trial to date, is a Phase 3 study assessing DBV's VIASKIN® Peanut Patch for the treatment of peanut-allergic children aged 4 to 7 years.

globenewswire.com

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting

Châtillon, France, February 10, 2026 DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the company will present additional data for the VIASKIN® Peanut Patch in children ages 4-7 years from the positive VITESSE Phase 3 study at the American Academy of Allergy, Asthma, and Immunology 2026 Annual Meeting, taking place in Philadelphia, PA February 27-March 2, 2026. The Company will also host a product theatre featuring a panel of renowned allergists discussing the potential of epicutaneous immunotherapy (EPIT) to reeducate the immune system in food allergy, examine the impact of early intervention in children with peanut allergy, and consider how emerging treatment options are enabling for a more proactive approach to peanut allergy management.

defenseworld.net

DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and

globenewswire.com

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026

globenewswire.com

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

Châtillon, France, January 16, 2026 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing The Company is sufficiently funded to support operations and commercial preparedness, including infrastructure buildup, to launch the VIASKIN® Peanut patch in children 4 to 7 years old in the U.S., if approved. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced a supplementary financing of €166.7 Million (the "Exercise") resulting from the full exercise of (i) 34,090,004 warrants attached to new ordinary shares issued by the Company on April 7, 2025 at an exercise price of €1.5939 (the "ABSA Warrants") resulting in the issuance of 59,657,507 new ordinary shares of the Company (the "New Shares") and (ii) 71,005,656 warrants issued by the Company on April 7, 2025 at an exercise price of €1.5764 (the "BS Warrants") resulting in the issuance of 71,005,656 pre-funded warrants (the "Second Pre-Funded Warrants"), allowing its holders to subscribe for an aggregate of up to 124,259,898 new shares.

globenewswire.com

Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

globenewswire.com

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

defenseworld.net

DBV Technologies (NASDAQ:DBVT) Shares Gap Down on Insider Selling

Shares of DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) gapped down before the market opened on Monday following insider selling activity. The stock had previously closed at $22.76, but opened at $20.67. DBV Technologies shares last traded at $20.2670, with a volume of 124,159 shares traded. Specifically, major shareholder Bpifrance Epic sold 1,292,103 shares

defenseworld.net

Bpifrance Epic Sells 1,292,103 Shares of DBV Technologies (NASDAQ:DBVT) Stock

DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) major shareholder Bpifrance Epic sold 1,292,103 shares of DBV Technologies stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $4.19, for a total value of $5,413,911.57. Following the completion of the transaction, the insider owned 7,303,369 shares of the

defenseworld.net

Bpifrance Epic Sells 2,076,990 Shares of DBV Technologies (NASDAQ:DBVT) Stock

DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report) major shareholder Bpifrance Epic sold 2,076,990 shares of the company's stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $4.85, for a total transaction of $10,073,401.50. Following the completion of the transaction, the insider directly owned 8,595,472 shares of

benzinga.com

Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing

DBV Technologies S.A. (NASDAQ: DBVT) on Tuesday released data from the VITESSE Phase 3 study assessing the safety and efficacy of VIASKIN Peanut patch for peanut-allergic children aged 4 to 7 years.

seekingalpha.com

DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript

247wallst.com

Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More

Pre-Market Stock Futures: Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard on Friday as investors began a big rotation last week out of the AI stocks that have led the market higher since ChatGPT was introduced over three years... Here Are Monday's Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More.

247wallst.com

Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More

Pre-Market Stock Futures: The futures are trading higher on Wednesday after a stellar day across Wall Street on Tuesday. All of the major indices finished the day higher, with the technology-heavy NASDAQ leading the way, closing up 0.59% at 23,413. The S&P 500 ended the session at 6,829, up 0.25% and the Dow Jones Industrials... Here Are Wednesday's Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy's and More.

globenewswire.com

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN ® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Company remains on track for VITESSE topline data in Q4 of this year DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the last patient visit has been completed in the Company's Phase 3 VITESSE clinical trial of the VIASKIN® Peanut patch in peanut allergic children aged 4-7 years. With the completion of the double-blind, placebo-controlled treatment phase of the study, DBV remains on track to announce topline data from VITESSE in the fourth quarter of this year.

globenewswire.com

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2 nd Annual Healthcare Innovation Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, at 2:00 p.m. ET in Boston, Massachusetts.

defenseworld.net

DBV Technologies (DBVT) Expected to Announce Quarterly Earnings on Wednesday

DBV Technologies (NASDAQ: DBVT - Get Free Report) is projected to issue its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($1.45) per share and revenue of $0.7570 million for the quarter. Parties can check the company's upcoming Q3 2025 earningsummary page for the latest

globenewswire.com

DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr.

zacks.com

Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?

Here is how DBV Technologies S.A. (DBVT) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance